[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020003487A - Compuestos inhibidores de pirimidina tbk/ikkepsilon y usos de los mismos. - Google Patents

Compuestos inhibidores de pirimidina tbk/ikkepsilon y usos de los mismos.

Info

Publication number
MX2020003487A
MX2020003487A MX2020003487A MX2020003487A MX2020003487A MX 2020003487 A MX2020003487 A MX 2020003487A MX 2020003487 A MX2020003487 A MX 2020003487A MX 2020003487 A MX2020003487 A MX 2020003487A MX 2020003487 A MX2020003487 A MX 2020003487A
Authority
MX
Mexico
Prior art keywords
pyrimidine
inhibitor compounds
inhibitor
compounds
empty
Prior art date
Application number
MX2020003487A
Other languages
English (en)
Inventor
Srinivasa R Karra
Yufang Xiao
Brian A Sherer
Eugene Chekler
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2020003487A publication Critical patent/MX2020003487A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polymerisation Methods In General (AREA)

Abstract

La presente invención se relaciona con compuestos de la Fórmula I y composiciones farmacéuticamente aceptables de los mismos, útiles como inhibidores de TBK/IKKe.
MX2020003487A 2017-10-17 2018-10-17 Compuestos inhibidores de pirimidina tbk/ikkepsilon y usos de los mismos. MX2020003487A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762573255P 2017-10-17 2017-10-17
PCT/US2018/056192 WO2019079375A1 (en) 2017-10-17 2018-10-17 IN / ΙΚΚΕ PYRIMIDINE INHIBITOR COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020003487A true MX2020003487A (es) 2020-07-22

Family

ID=64110186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003487A MX2020003487A (es) 2017-10-17 2018-10-17 Compuestos inhibidores de pirimidina tbk/ikkepsilon y usos de los mismos.

Country Status (15)

Country Link
US (1) US11440899B2 (es)
EP (1) EP3697773A1 (es)
JP (1) JP7284161B2 (es)
KR (1) KR20200071756A (es)
CN (1) CN111247134A (es)
AU (1) AU2018352701A1 (es)
BR (1) BR112020007549A2 (es)
CA (1) CA3078583A1 (es)
IL (1) IL273892A (es)
MX (1) MX2020003487A (es)
RU (1) RU2020115295A (es)
SG (1) SG11202003441VA (es)
TW (1) TWI802605B (es)
WO (1) WO2019079375A1 (es)
ZA (1) ZA202002825B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022245085A1 (ko) 2021-05-17 2022-11-24 보로노이바이오 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203092A1 (en) 2000-08-08 2005-09-15 Benjamin Elfrida R. 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
AU2001281120A1 (en) * 2000-08-08 2002-02-18 Ortho-Mcneil Pharmaceutical, Inc. 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
EP1678147B1 (en) * 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
EP1901747A2 (en) * 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
JP2013507449A (ja) 2009-10-12 2013-03-04 ミレクシス， インコーポレイテッド ＴＢＫ１および／またはＩＫＫεの阻害剤としてのアミノ−ピリミジン化合物
GB201012105D0 (en) 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
JP2014510794A (ja) * 2011-04-12 2014-05-01 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド ＩＫＫ関連キナーゼεおよびＴＡＮＫ結合キナーゼ１の阻害剤の組成物および治療的使用
DE102011112978A1 (de) * 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
RU2622034C2 (ru) 2012-02-09 2017-06-09 Мерк Патент Гмбх ПРОИЗВОДНЫЕ ФУРО[3,2-В]- И ТИЕНО[3,2-В]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TBK1 И IKKε
WO2013175415A1 (en) 2012-05-23 2013-11-28 Piramal Enterprises Limited Substituted pyrimidine compounds and uses thereof
TW201418243A (zh) * 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
GB201303109D0 (en) * 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
ES2881195T3 (es) * 2014-09-26 2021-11-29 Gilead Sciences Inc Derivados de aminotriazina útiles como compuestos inhibidores de quinasas que se unen a TANK
JP2018524350A (ja) * 2015-06-29 2018-08-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ＴＢＫ／ＩＫＫε阻害剤化合物及びその用途
CN106928216A (zh) * 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
WO2019079373A1 (en) * 2017-10-17 2019-04-25 Merck Patent Gmbh PYRIMIDINE TBK / IKKε INHIBITORY COMPOUNDS AND USES THEREOF

Also Published As

Publication number Publication date
WO2019079375A1 (en) 2019-04-25
US20210214339A1 (en) 2021-07-15
IL273892A (en) 2020-05-31
EP3697773A1 (en) 2020-08-26
KR20200071756A (ko) 2020-06-19
RU2020115295A (ru) 2021-11-18
US11440899B2 (en) 2022-09-13
CA3078583A1 (en) 2019-04-25
BR112020007549A2 (pt) 2020-09-24
TW201922729A (zh) 2019-06-16
JP7284161B2 (ja) 2023-05-30
AU2018352701A1 (en) 2020-06-04
RU2020115295A3 (es) 2021-11-18
JP2020537661A (ja) 2020-12-24
TWI802605B (zh) 2023-05-21
ZA202002825B (en) 2023-05-31
SG11202003441VA (en) 2020-05-28
CN111247134A (zh) 2020-06-05

Similar Documents

Publication Publication Date Title
HUS2400019I1 (hu) KRas G12C inhibotorok
MX2020004084A (es) Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion.
MX2020003596A (es) Composiciones de acido nucleico-polipeptido y usos de las mismos.
MX2020003579A (es) Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
MX2020004287A (es) Procesamiento de biomasa.
IL280593A (en) pyrrolopyrimidine itk inhibitors
MX2020003430A (es) Derivados de 1-bencil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de proteasa de virus de inmunodeficiencia humana.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2017000363A (es) Inhibicion de la via de notch.
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2020004255A (es) Compuesto de pirimidina como inhibidor de las janocinasas.
MX2020003760A (es) Formulaciones de niraparib.
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
MX2020003421A (es) Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
MX2020004424A (es) Formulacion aerosolizable.
SG10201913927VA (en) Kinase inhibitors and uses thereof
MX2020004455A (es) Derivados de pirrolopirazina como inhibidores de integrina alfa v.
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
MX2020004241A (es) Conector y montaje de conector.
MX2020004107A (es) Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas.
MX2020003523A (es) Deteccion de dimetilarginina simetrica.
MX2020003439A (es) Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1).
MX2020003507A (es) Compuestos pirimidinicos inhibidores de (tbk)/(ikk) epsilon y usos de los mismos.
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.